- Home
- XPRO vs INBX Comparison
XPRO vs INBX Comparison
Compare XPRO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XPRO | INBX |
|---|---|---|
| Founded | 1938 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2026 | 2024 |
Fundamental Metrics
Financial Performance| Metric | XPRO | INBX |
|---|---|---|
| Price | $16.30 | $97.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $17.50 | ★ $266.67 |
| AVG Volume (30 Days) | ★ 665.8K | 282.4K |
| Earning Date | 10-22-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $6.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $11.92 | $28.16 |
| 52 Week High | $19.23 | $155.29 |
Technical Indicators
Market Signals| Indicator | XPRO | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 43.08 |
| Support Level | $15.37 | $96.60 |
| Resistance Level | $17.09 | $106.40 |
| Average True Range (ATR) | 0.63 | 5.75 |
| MACD | -0.15 | -1.44 |
| Stochastic Oscillator | 6.52 | 11.13 |
Price Performance
Historical ComparisonAbout XPRO Expro Group Holdings N.V.
Expro Ltd is an energy services company that provides energy services and well solutions for the oil and gas industry. Its service portfolio includes well construction, well flow management, subsea well access, well intervention, and well integrity solutions. The company serves exploration and production companies in onshore and offshore environments across multiple countries.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.